Evidence map›Paper›PMID 37985002›Full record

Trial reportESC heart failure2024

Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY-HFpEF trial.

Javed Butler, Muhammad Shahzeb Khan, Tomasz Gasior, Tyler R Erickson, Vanja Vlajnic, Frank Kramer, Robert O Blaustein, David Goldsbury, Lothar Roessig, Carolyn S P Lam and 3 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 6 countries.

Javed ButlerBaylor Scott and White Research Institute, Dallas, TX, USA.
Muhammad Shahzeb KhanDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Tomasz GasiorBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Tyler R EricksonDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Vanja VlajnicBayer US LLC, Whippany, NJ, USA.
Frank KramerBayer AG, Wuppertal, Germany.
Robert O BlausteinMerck & Co., Inc., Rahway, NJ, USA.
David GoldsburyBayer PLC, Reading, UK.
Lothar RoessigBayer AG, Wuppertal, Germany.
Carolyn S P LamNational Heart Centre Singapore and Duke-National University of Singapore, Singapore.
Kevin J AnstromUniversity of North Carolina, Chapel Hill, NC, USA.
Paul W ArmstrongCanadian VIGOUR Centre, University of Alberta, Katz Group Centre for Pharmacy and Health Research, 4-120, Edmonton, T6G 2E1, AB, Canada.
VITALITY Study Group
Bayer (Germany) · DEBayer (United States) · USBoehringer Ingelheim (Germany) · DEClinical Research Institute · USDuke University · USJackson Memorial Hospital · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USNational Heart Centre Singapore · SGUniversity of Alberta · CAUniversity of North Carolina at Chapel Hill · US

Funding

BayerMerck Sharp & Dohme Corp.
6 · The paper itself

Abstract

aimsThe relationship between accelerometry data and changes in Kansas City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) or 6 min walk test (6MWT) is not well understood. METHODS AND

resultsVITALITY-HFpEF accelerometry substudy (n = 69) data were assessed at baseline and 24 weeks. Ordinal logistic regression models were used to assess the association between accelerometry activity and deterioration, improved, or unchanged KCCQ-PLS (≥8.33 and ≤ -4.17 points) and 6MWT (≥32 vs. ≤ -32 m). KCCQ-PLS score deteriorated in 16 patients, improved in 34, and was unchanged in 19. 6MWT deteriorated in 8 patients, improved in 21, and was unchanged in 19. Mean accelerometer wear was 21.4 (±2.1) h/day. Changes in hours active from baseline to 24 weeks were not significantly different among patients who exhibited deterioration, improvement, or no change in KCCQ-PLS [odds ratio (OR) 0.91, 95% confidence interval (CI) 0.71-1.18; P = 0.48] or 6MWT (OR 1.21, 95% CI 0.91-1.60; P = 0.18). Similar lack of association was observed for other accelerometry metrics and change in KCCQ and 6MWT. These findings were unaffected when KCCQ and 6MWT were examined as continuous variables.

conclusionsAccelerometer-based activity measures did not correlate with subjective or objective standard measures of health status and functional capacity in heart failure with preserved ejection fraction. Further investigation of their relationships to clinical outcomes is required.

Indexed as

Heart FailureAccelerometryHealth StatusHumansQuality of LifeStroke Volume6 min walk testAccelerometeryHeart failure with preserved ejection fractionKansas City Cardiomyopathy Questionnaire-Physical Limitation Score

Identifiers

PMID37985002
PMCPMC10804173
OpenAlexW4388865332

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.